Faecal microbiota transplantation for severe, refractory Clostridioides difficile infection: a multicentre real‐world experience
Internal Medicine Journal · 13.11.2026
DOI: 10.1111/imj.70702 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 13.11.2026. Verfasst von Andrew Chin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Background
Severe Clostridioides difficile infection (CDI) is associated with substantial morbidity and mortality. Although most patients respond to CDI‐directed antimicrobial therapy, a subset develops refractory disease. Faecal microbiota transplantation (FMT) is established for recurrent CDI, but data supporting its use in severe, refractory CDI remain limited.
Aims
To evaluate the safety and effectiveness of FMT in hospitalised patients with severe, refractory CDI across tertiary centres.
Methods
This was a retrospective multicentre study of adults with severe, refractory CDI who underwent FMT at three tertiary hospitals in Western Australia between January 2021 and April 2025. Severe CDI was defined according to Australasian Society of Infectious Diseases criteria and refractory disease as failure to demonstrate clinical improvement following appropriate CDI‐directed antimicrobial therapy. Primary cure was defined as resolution without recurrence within 90 days following a single FMT. Secondary outcomes included secondary cure, colectomy, FMT‐related complications and hospital length of stay.
Results
Fourteen patients underwent FMT for severe, refractory CDI. Median age was 68.5 years (range 32–84), 57.1% were female, and 71.4% were immunosuppressed. Median Charlson Comorbidity Index was 5.5 (range 0–11). FMT was delivered via colonoscopy, flexible sigmoidoscopy or nasogastric tube. Median sessions was 1.5 (range 1–4); five (35.7%) patients received consolidative antibiotics following repeat FMT. Primary cure after a single FMT was achieved in seven (50%) patients. The remaining seven required repeat FMT, with a secondary cure rate of 100% at 3 months. One patient died from an unrelated cause. No patients required colectomy, experienced recurrence or FMT‐related complications. Median hospital stay was 24.5 days (range 7–65).
Conclusion
FMT was associated with high rates of clinical cure as salvage therapy for hospitalised patients with severe, refractory CDI. While only half achieved primary cure after a single FMT, sequential FMT achieved a secondary cure rate of 100%. Further studies are needed to define optimal treatment protocols.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
- Department of Gastroenterology and Hepatology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
- Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, Western Australia, Australia.
- Department of Infectious Disease, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
ORCID-Profile: Andrew Chin, Shankar Menon
Zitieren
APA
Chin, A., Gardner, C., Menon, S., Makanyanga, J., Gliddon, T., Li, A., & Waters, O. (2026). Faecal microbiota transplantation for severe, refractory Clostridioides difficile infection: a multicentre real‐world experience. Internal Medicine Journal. https://doi.org/10.1111/imj.70702
Vancouver
Chin A, Gardner C, Menon S, Makanyanga J, Gliddon T, Li A, et al. Faecal microbiota transplantation for severe, refractory Clostridioides difficile infection: a multicentre real‐world experience. Internal Medicine Journal. 2026. doi:10.1111/imj.70702
BibTeX
@article{Chin2026,
author = {Chin, Andrew and Gardner, Claudia and Menon, Shankar and Makanyanga, Jesica and Gliddon, Thomas and Li, Angel and Waters, Oliver},
title = {Faecal microbiota transplantation for severe, refractory Clostridioides difficile infection: a multicentre real‐world experience},
journal = {Internal Medicine Journal},
year = {2026},
doi = {10.1111/imj.70702}
}
EUVIMED